Takeda Pharmaceutical concludes sale of OTC and non-core assets to Orifarm for $670m
Takeda Pharmaceutical Company has completed the previously announced sale of a portfolio of select over-the-counter (OTC) pharma products and non-core assets to Orifarm Group for $670m. The latest
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.